WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016061064) CIRCULATING TUMOR CELL DIAGNOSTICS FOR THERAPY TARGETING PD-L1
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/061064    International Application No.:    PCT/US2015/055275
Publication Date: 21.04.2016 International Filing Date: 13.10.2015
IPC:
G01N 33/574 (2006.01)
Applicants: EPIC SCIENCES, INC. [US/US]; 9381 Judicial Drive Suite 200 San Diego, CA 92121 (US)
Inventors: DITTAMORE, Ryan; (US)
Agent: SPAIN, Astrid, R.; (US)
Priority Data:
62/064,320 15.10.2014 US
Title (EN) CIRCULATING TUMOR CELL DIAGNOSTICS FOR THERAPY TARGETING PD-L1
(FR) DIAGNOSTIC DE CELLULES TUMORALES CIRCULANTES POUR UNE THÉRAPIE CIBLÉE À PD-L1
Abstract: front page image
(EN)The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level.
(FR)La présente invention porte sur un procédé de détermination du point de savoir si un sujet atteint d'un cancer est un candidat pour une immunothérapie ciblée à ligand-1 à mort programmée (PD-L1), lequel procédé consiste (a) à fournir un échantillon de biopsie liquide obtenu d'un sujet atteint d'un cancer; (b) à détecter des CTC dans l'échantillon de biopsie liquide; (c) à calculer quelle proportion de CTC dans la biopsie liquide exprime PD-L1; et (c) à identifier le sujet en tant que candidat pour une immunothérapie ciblée à PD-L1 sur la base d'une évaluation que la proportion des CTC dans la biopsie liquide qui exprime PD-L1 dépasse un niveau de seuil prédéterminé.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)